Published in J Clin Oncol on November 01, 2006
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother (2008) 2.57
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci U S A (2010) 2.01
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One (2009) 1.51
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med (2009) 1.44
Adoptive cell transfer therapy. Semin Oncol (2007) 1.44
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol (2009) 1.36
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res (2009) 1.15
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother (2009) 1.09
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother (2008) 0.99
PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci (2008) 0.96
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol Immunother (2010) 0.95
Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A (2013) 0.95
Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol (2011) 0.94
Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev (2014) 0.93
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (2011) 0.92
Materials based tumor immunotherapy vaccines. Curr Opin Immunol (2013) 0.92
Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One (2012) 0.91
Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother (2008) 0.91
Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 0.91
A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol (2010) 0.90
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol (2013) 0.90
Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol (2012) 0.90
Rapid multitarget immunomagnetic separation through programmable DNA linker displacement. J Am Chem Soc (2011) 0.89
Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers. Mol Cell Proteomics (2010) 0.88
Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother (2012) 0.88
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother (2012) 0.88
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Current advances in T-cell-based cancer immunotherapy. Immunotherapy (2014) 0.86
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother (2012) 0.85
Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'. Immunotherapy (2010) 0.85
Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunol Res (2013) 0.84
Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. Sci Rep (2015) 0.84
Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol (2015) 0.84
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy (2007) 0.84
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. Br J Cancer (2013) 0.82
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. J Immunol Res (2015) 0.81
Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochim Biophys Acta (2014) 0.81
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest (2016) 0.80
Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer. Exp Ther Med (2014) 0.80
Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res (2014) 0.80
Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. J Control Release (2014) 0.80
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med (2014) 0.80
Novel delivery methods to achieve immunomodulation. Curr Opin Pharmacol (2007) 0.80
Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. PLoS One (2010) 0.80
Dynamic tracing of immune cells in an orthotopic gastric carcinoma mouse model using near-infrared fluorescence live imaging. Exp Ther Med (2012) 0.80
T lymphocytes targeting native receptors. Immunol Rev (2014) 0.80
Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother (2014) 0.80
Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. J Skin Cancer (2011) 0.79
Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy. J Transl Med (2008) 0.79
An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther (2011) 0.78
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma. Cancers (Basel) (2012) 0.78
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano (2015) 0.78
Targeting c-MYC with T-cells. PLoS One (2013) 0.78
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid (2014) 0.77
A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol (2013) 0.77
Autocrine, not paracrine, interferon-gamma gene delivery enhances ex vivo antigen-specific cytotoxic T lymphocyte stimulation and killing. J Biomed Biotechnol (2010) 0.77
Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy. J Biomed Biotechnol (2010) 0.76
Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma. BMC Immunol (2011) 0.76
Advances in cellular therapy for the treatment of thyroid cancer. J Oncol (2010) 0.76
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. Haematologica (2012) 0.76
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. Mol Ther (2014) 0.76
Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells. Oncoimmunology (2016) 0.76
Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight (2017) 0.75
How to detour Treg cells in T cell-based antitumor immune therapy. Onco Targets Ther (2013) 0.75
Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy. J Transl Med (2011) 0.75
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. Cancer Res (2008) 0.75
Advances in immunotherapy for melanoma management. Hum Vaccin Immunother (2016) 0.75
Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. Elife (2016) 0.75
Cancer Immunotherapies: Are They as Effective in the Elderly? Drugs Aging (2017) 0.75
In Vivo Murine-Matured Human CD3(+) Cells as a Preclinical Model for T Cell-Based Immunotherapies. Mol Ther Methods Clin Dev (2017) 0.75
Expression and immunogenicity of NY-ESO-1 in colorectal cancer. Exp Ther Med (2017) 0.75
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res (2009) 2.87
Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood (2004) 2.76
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 2.64
Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood (2006) 2.57
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res (2006) 2.22
Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol (2009) 2.22
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res (2004) 1.92
Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood (2014) 1.80
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood (2004) 1.76
General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res (2010) 1.64
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2005) 1.58
Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. J Invest Dermatol (2011) 1.51
Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood (2004) 1.49
Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood (2003) 1.47
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood (2006) 1.45
Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood (2004) 1.40
Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem (2003) 1.39
Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. Blood (2012) 1.36
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol (2003) 1.36
Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant (2006) 1.32
Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol (2009) 1.22
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. Genome Biol (2010) 1.20
Transcription and enhancer profiling in human monocyte subsets. Blood (2014) 1.12
Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. Eur J Immunol (2011) 1.09
The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood (2014) 1.08
Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology (2006) 1.07
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res (2007) 1.06
Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol (2006) 0.99
An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods (2002) 0.99
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol (2013) 0.98
Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. J Immunol (2011) 0.97
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer (2004) 0.97
Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res (2006) 0.97
Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions. Cell Cycle (2006) 0.96
Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood (2002) 0.96
Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation. Immunology (2003) 0.95
5-Hydroxymethylcytosine is an essential intermediate of active DNA demethylation processes in primary human monocytes. Genome Biol (2013) 0.94
LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol (2003) 0.94
The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother (2002) 0.94
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer (2011) 0.94
CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res (2007) 0.93
Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor. J Immunol (2005) 0.92
High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res (2004) 0.91
Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood (2011) 0.91
Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine (2004) 0.91
Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology (2002) 0.90
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol (2006) 0.89
Expression and function of homing-essential molecules and enhanced in vivo homing ability of human peripheral blood-derived hematopoietic progenitor cells after stimulation with stem cell factor. Stem Cells (2004) 0.87
Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun (2006) 0.87
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2004) 0.87
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother (2005) 0.87
Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther (2007) 0.86
Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients. Transplantation (2005) 0.86
Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2008) 0.86
A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome. Transplantation (2005) 0.84
Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Ann Hematol (2011) 0.84
Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation. Clin Cancer Res (2004) 0.83
Isolation and transplantation of allogeneic pulmonary endothelium derived from GFP transgenic mice. J Immunol Methods (2003) 0.83
C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. Biomark Insights (2007) 0.83
Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol (2010) 0.82
A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody. Rheumatol Int (2002) 0.81
CD84 expression on human hematopoietic progenitor cells. Exp Hematol (2003) 0.81
Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease. Int J Hematol (2009) 0.81
Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells. Immunology (2005) 0.81
Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocyte-derived dendritic cells. Genomics (2002) 0.81
NOD2/CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters. J Clin Oncol (2008) 0.81
Identification of genes expressed in tumor-associated macrophages. Immunobiology (2003) 0.81
RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother (2010) 0.81
Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation. Int J Mol Med (2007) 0.81
Palliative care needs, symptoms, and treatment intensity along the disease trajectory in medical oncology outpatients: a retrospective chart review. Support Care Cancer (2013) 0.80
Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun (2002) 0.80
Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. Exp Hematol (2010) 0.79
Isolation of intact genomic DNA from FOXP3-sorted human regulatory T cells for epigenetic analyses. Eur J Immunol (2010) 0.79
Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation (2004) 0.79
New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells. PLoS One (2013) 0.79
Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells. Eur J Immunol (2012) 0.79
Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother (2004) 0.79
Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin. Eur J Haematol (2007) 0.79
Direct evidence of endothelial injury during cardiopulmonary bypass by demonstration of circulating endothelial cells. Perfusion (2006) 0.79
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol (2009) 0.78
TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. Med Mycol (2013) 0.78
Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. J Antimicrob Chemother (2007) 0.77
Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. Exp Hematol (2007) 0.77
Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach. Int J Colorectal Dis (2013) 0.77
Peripheral dendritic cell chimerism in allogeneic hematopoietic stem cell recipients. Transplantation (2005) 0.77